Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells

Targeted agents and immunotherapies: optimizing outcomes in melanoma

(2017) Jason J. Luke et al.   Nature Reviews Clinical Oncology

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas

(2017) Maria Vincenza Carriero et al.   Scientific Reports

Multiple mechanisms of 3D migration: the origins of plasticity

(2016) Ryan J Petrie et al.   CURRENT OPINION IN CELL BIOLOGY

A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma

(2016) Fanny Matheis et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells

(2016) Vincenzo Ingangi et al.   Oncotarget

Extracellular acidity strengthens mesenchymal stem cells to promote melanoma progression

(2015) Silvia Peppicelli et al.   CELL CYCLE

Formylpeptide receptor 1 mediates the tumorigenicity of human hepatocellular carcinoma cells

(2015) Liang Zhang et al.   OncoImmunology

The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style

(2015) Francesca Margheri et al.   Oncotarget

3D cell culture systems modeling tumor growth determinants in cancer target discovery

(2014) Claudio R. Thoma et al.   ADVANCED DRUG DELIVERY REVIEWS

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

(2014) Paolo A Ascierto et al.   Journal of Translational Medicine

UPARANT: A Urokinase Receptor-Derived Peptide Inhibitor of VEGF-Driven Angiogenesis with Enhanced Stability and In Vitro and In Vivo Potency

(2014) M. V. Carriero et al.   MOLECULAR CANCER THERAPEUTICS

Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)

(2014) SADEK MALAS et al.   ONCOLOGY REPORTS

The melanoma revolution: From UV carcinogenesis to a new era in therapeutics

(2014) J. A. Lo et al.   SCIENCE

Opposite Modulation of Cell Migration by Distinct Subregions of Urokinase Connecting Peptide

(2013) Paola Franco et al.   CHEMBIOCHEM

A Urokinase Receptor-Derived Peptide Inhibiting VEGF-Dependent Directional Migration and Vascular Sprouting

(2013) K. Bifulco et al.   MOLECULAR CANCER THERAPEUTICS

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

Differential Expression of the G-Protein–Coupled Formyl Peptide Receptor in Melanoma Associates With Aggressive Phenotype

(2012) Nitin Chakravarti et al.   AMERICAN JOURNAL OF DERMATOPATHOLOGY

G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma

(2012) Mingyong Liu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Crystal Structure of the Urokinase Receptor in a Ligand-Free Form

(2012) Xiang Xu et al.   JOURNAL OF MOLECULAR BIOLOGY

Single Amino Acid Substitutions in the Chemotactic Sequence of Urokinase Receptor Modulate Cell Migration and Invasion

(2012) Katia Bifulco et al.   PLoS One

The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling

(2011) Maria Vincenza Carriero et al.   CURRENT PHARMACEUTICAL DESIGN

Conformational Regulation of Urokinase Receptor Function

(2011) Henrik Gårdsvoll et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The cephalic neural crest of amniote vertebrates is composed of a large majority of precursors endowed with neural, melanocytic, chondrogenic and osteogenic potentialities

(2010) Elisabeth Dupin et al.   CELL CYCLE

The soluble form of urokinase receptor promotes angiogenesis through its Ser88-Arg-Ser-Arg-Tyr92 chemotactic sequence

(2010) K. BIFULCO et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling

(2009) Francesco Blasi et al.   FEBS LETTERS

Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis

(2009) M. V. Carriero et al.   MOLECULAR CANCER THERAPEUTICS

Regulation of cell signalling by uPAR

(2009) Harvey W. Smith et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family

(2009) R. D. Ye et al.   PHARMACOLOGICAL REVIEWS

Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement

(2008) Victoria Sanz-Moreno et al.   CELL

Urokinase Plasminogen Activator Receptor Choreographs Multiple Ligand Interactions: Implications for Tumor Progression and Therapy

(2008) A. P. Mazar   CLINICAL CANCER RESEARCH

The Urokinase Receptor and its Structural Homologue C4.4A in Human Cancer: Expression, Prognosis and Pharmacological Inhibition

(2008) B. Jacobsen et al.   CURRENT MEDICINAL CHEMISTRY

Integrin αvβ3-targeted cancer therapy

(2008) Zhaofei Liu et al.   DRUG DEVELOPMENT RESEARCH

An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor

(2008) Katia Bifulco et al.   FEBS LETTERS